Jing leads the development of our technology platform and oversees the clinical manufacture of virus-like particles.
He has extensive experience in progressing vaccines and therapeutics from early stage research to clinical trials. Before leaving academia to set up SpyBiotech in early 2017, he was a Senior Associate at Oxford University’s renown Jenner Institute delivering cGMP projects for protein and virus-like particle vaccine candidates.
He has also worked in industry. During his time at Native Antigen Company, he led the development and eventual commercial launch of novel viral and bacterial antigens for the IVD market
Jing completed his PhD in Biochemical Engineering for virus-like particle platform development at University College London’s Innovative Manufacturing Research Centre in Bioprocessing.